Next 10 |
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Mymetics Corporation (MYMX) is expected to report for Q1 2024
Switzerland-based Mymetics ( OTCQB:MYMX ) and Norwegian cancer focused company PCI Biotech entered a preclinical research collaboration to explore technological synergies for potentially better cancer therapy. The project is the first step to decide if there is a basi...
EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharma...
Mymetics (MYMX) subsidiary and Insel Gruppe AG have been awarded a grant from the Swiss Innovation Agency, which will allow Mymetics in collaboration with Bern University to start a preclinical study investigating MYMX's virosome-based COVID-19 nasal vaccine candidate to block nasal infection...
Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation ...
Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. Under the TRANSVAC2 program, funded by the European Com...
Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. In May 2020 Mymetics and Baylor College of ...
Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine The European vaccine infrastructure, TRANSVAC2, funded by the Eu...
News, Short Squeeze, Breakout and More Instantly...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Mymetics Corporation (MYMX) is expected to report for Q1 2024